The University of Southampton
University of Southampton Institutional Repository

Ablation of the dystrophin Dp71f alternative C-terminal variant increases sarcoma tumour cell aggressiveness

Ablation of the dystrophin Dp71f alternative C-terminal variant increases sarcoma tumour cell aggressiveness
Ablation of the dystrophin Dp71f alternative C-terminal variant increases sarcoma tumour cell aggressiveness

Alterations in Dp71 expression, the most ubiquitous dystrophin isoform, have been associated with patient survival across tumours. Intriguingly, in certain malignancies, Dp71 acts as a tumour suppressor, while manifesting oncogenic properties in others. This diversity could be explained by the expression of two Dp71 splice variants encoding proteins with distinct C-termini, each with specific properties. Expression of these variants has impeded the exploration of their unique roles. Using CRISPR/Cas9, we ablated the Dp71f variant with the alternative C-terminus in a sarcoma cell line not expressing the canonical C-terminal variant, and conducted molecular (RNAseq) and functional characterisation of the knockout cells. Dp71f ablation induced major transcriptomic alterations, particularly affecting the expression of genes involved in calcium signalling and ECM-receptor interaction pathways. The genome-scale metabolic analysis identified significant downregulation of glucose transport via membrane vesicle reaction (GLCter) and downregulated glycolysis/gluconeogenesis pathway. Functionally, these molecular changes corresponded with, increased calcium responses, cell adhesion, proliferation, survival under serum starvation and chemotherapeutic resistance. Knockout cells showed reduced GLUT1 protein expression, survival without attachment and their migration and invasion in vitro and in vivo were unaltered, despite increased matrix metalloproteinases release. Our findings emphasise the importance of alternative splicing of dystrophin transcripts and underscore the role of the Dp71f variant, which appears to govern distinct cellular processes frequently dysregulated in tumour cells. The loss of this regulatory mechanism promotes sarcoma cell survival and treatment resistance. Thus, Dp71f is a target for future investigations exploring the intricate functions of specific DMD transcripts in physiology and across malignancies.

0964-6906
Alnassar, Nancy
3d6e9d70-eb41-4fef-bace-dac12d3aee73
Hajto, Jacek
8a9c553a-856e-44fc-843f-e82a3a47832c
Rumney, Robin M.H.
fa3de9f8-b604-44e2-9e72-3e57980ce67f
Verma, Suraj
f4c72a4f-faf3-477d-8d2d-f6e1db9202e2
Borczyk, Malgorzata
bdbe94f5-5adf-4ae5-8acb-cf18fdba1d85
Saha, Chandrika
2b1dfcdc-a6bc-4987-bc3b-deaab7188365
Kanczler, Janos
eb8db9ff-a038-475f-9030-48eef2b0559c
Butt, Arthur M.
381a0c45-e817-4f3c-90d9-3f8cf020fd12
Occhipinti, Annalisa
3aa3cf0e-41dd-42de-9745-f85ff813238a
Pomeroy, Joanna
c5b97493-ad09-443a-a90a-2cbee0a9ea08
Angione, Claudio
1c81131d-d828-42c0-9c3a-3c63c45208ac
Korostynski, Michal
243991b4-c093-4674-ba95-d2e236d44b82
Górecki, Dariusz C.
6406abcf-0561-40dc-b41f-32f55795eb04
Alnassar, Nancy
3d6e9d70-eb41-4fef-bace-dac12d3aee73
Hajto, Jacek
8a9c553a-856e-44fc-843f-e82a3a47832c
Rumney, Robin M.H.
fa3de9f8-b604-44e2-9e72-3e57980ce67f
Verma, Suraj
f4c72a4f-faf3-477d-8d2d-f6e1db9202e2
Borczyk, Malgorzata
bdbe94f5-5adf-4ae5-8acb-cf18fdba1d85
Saha, Chandrika
2b1dfcdc-a6bc-4987-bc3b-deaab7188365
Kanczler, Janos
eb8db9ff-a038-475f-9030-48eef2b0559c
Butt, Arthur M.
381a0c45-e817-4f3c-90d9-3f8cf020fd12
Occhipinti, Annalisa
3aa3cf0e-41dd-42de-9745-f85ff813238a
Pomeroy, Joanna
c5b97493-ad09-443a-a90a-2cbee0a9ea08
Angione, Claudio
1c81131d-d828-42c0-9c3a-3c63c45208ac
Korostynski, Michal
243991b4-c093-4674-ba95-d2e236d44b82
Górecki, Dariusz C.
6406abcf-0561-40dc-b41f-32f55795eb04

Alnassar, Nancy, Hajto, Jacek, Rumney, Robin M.H., Verma, Suraj, Borczyk, Malgorzata, Saha, Chandrika, Kanczler, Janos, Butt, Arthur M., Occhipinti, Annalisa, Pomeroy, Joanna, Angione, Claudio, Korostynski, Michal and Górecki, Dariusz C. (2024) Ablation of the dystrophin Dp71f alternative C-terminal variant increases sarcoma tumour cell aggressiveness. Human Molecular Genetics, [ddae094]. (doi:10.1093/hmg/ddae094).

Record type: Article

Abstract

Alterations in Dp71 expression, the most ubiquitous dystrophin isoform, have been associated with patient survival across tumours. Intriguingly, in certain malignancies, Dp71 acts as a tumour suppressor, while manifesting oncogenic properties in others. This diversity could be explained by the expression of two Dp71 splice variants encoding proteins with distinct C-termini, each with specific properties. Expression of these variants has impeded the exploration of their unique roles. Using CRISPR/Cas9, we ablated the Dp71f variant with the alternative C-terminus in a sarcoma cell line not expressing the canonical C-terminal variant, and conducted molecular (RNAseq) and functional characterisation of the knockout cells. Dp71f ablation induced major transcriptomic alterations, particularly affecting the expression of genes involved in calcium signalling and ECM-receptor interaction pathways. The genome-scale metabolic analysis identified significant downregulation of glucose transport via membrane vesicle reaction (GLCter) and downregulated glycolysis/gluconeogenesis pathway. Functionally, these molecular changes corresponded with, increased calcium responses, cell adhesion, proliferation, survival under serum starvation and chemotherapeutic resistance. Knockout cells showed reduced GLUT1 protein expression, survival without attachment and their migration and invasion in vitro and in vivo were unaltered, despite increased matrix metalloproteinases release. Our findings emphasise the importance of alternative splicing of dystrophin transcripts and underscore the role of the Dp71f variant, which appears to govern distinct cellular processes frequently dysregulated in tumour cells. The loss of this regulatory mechanism promotes sarcoma cell survival and treatment resistance. Thus, Dp71f is a target for future investigations exploring the intricate functions of specific DMD transcripts in physiology and across malignancies.

Text
ddae094 - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

Accepted/In Press date: 30 May 2024
e-pub ahead of print date: 9 June 2024
Published date: 9 June 2024

Identifiers

Local EPrints ID: 491310
URI: http://eprints.soton.ac.uk/id/eprint/491310
ISSN: 0964-6906
PURE UUID: 95b0f24f-0a62-46f1-812d-1dd7063ee6e7
ORCID for Janos Kanczler: ORCID iD orcid.org/0000-0001-7249-0414

Catalogue record

Date deposited: 19 Jun 2024 16:49
Last modified: 15 Aug 2024 01:39

Export record

Altmetrics

Contributors

Author: Nancy Alnassar
Author: Jacek Hajto
Author: Robin M.H. Rumney
Author: Suraj Verma
Author: Malgorzata Borczyk
Author: Chandrika Saha
Author: Janos Kanczler ORCID iD
Author: Arthur M. Butt
Author: Annalisa Occhipinti
Author: Joanna Pomeroy
Author: Claudio Angione
Author: Michal Korostynski
Author: Dariusz C. Górecki

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×